INVESTORS & MEDIA

Press Releases

Date Title and Summary View
Toggle Summary Atara Biotherapeutics Announces Six of Ten Progressive Multiple Sclerosis (MS) Patients Experienced Clinical Improvements in an Ongoing Phase 1 Study of Autologous ATA190
Three patients in the study improved their Expanded Disability Status Scale (EDSS) score Reduction in fatigue was a consistent observation in responding patients, as highlighted in a presentation at the MSParis 2017 Congress SOUTH SAN FRANCISCO, Calif., Oct.
View HTML
Toggle Summary Atara Biotherapeutics Initiates 60 Patient, Global Phase 1 Clinical Study to Evaluate Allogeneic ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis (MS)
Enrollment to begin in Australia; U.S. sites expected to open in early 2018 SOUTH SAN FRANCISCO, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf", or allogeneic, T-cell immunotherapy company developing novel treatments for patients with
View HTML
Toggle Summary Atara Biotherapeutics Announces Abstract Publication for Two MSParis2017 Congress Presentations, Including Updated Interim Results from a Phase 1 Study of Autologous ATA190 in Patients with Progressive Multiple Sclerosis (MS)
Five of eight progressive MS patients who received the full course of autologous ATA190 experienced clinical improvements Further results for all 10 patients in the ongoing Phase 1 study will be presented at the MSParis 2017 Congress SOUTH SAN FRANCISCO, Calif., Oct.
View HTML
Toggle Summary Atara Biotherapeutics Receives Positive Health Canada Regulatory Feedback for ATA129
Health Canada New Drug Submission (NDS) planned based on Phase 1 and 2 clinical results and supported by available data from anticipated MATCH and ALLELE Phase 3 studies, which are expected to be ongoing at the time of NDS filing Health Canada regulatory feedback similar to scientific advice from
View HTML
Toggle Summary Atara Biotherapeutics Receives FDA Orphan Drug Designation for ATA230
SOUTH SAN FRANCISCO, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for patients with cancer and autoimmune diseases, today announced that ATA230 was granted orphan drug
View HTML
Toggle Summary Atara Biotherapeutics to Participate in Three Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for patients with cancer and multiple sclerosis (MS) today announced that the Company will participate in
View HTML
Toggle Summary Atara Biotherapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Aug. 22, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for patients with cancer and multiple sclerosis (MS), today announced that Atara's board of directors approved
View HTML
Toggle Summary Atara Biotherapeutics Expands Leadership Team with the Appointment of Dr. Kanya Rajangam as Senior Vice President and Chief Medical Officer
SOUTH SAN FRANCISCO, Calif., Aug. 22, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for patients with cancer and multiple sclerosis (MS), today announced the appointment of Kanya Rajangam, M.D.,
View HTML
Toggle Summary Atara Biotherapeutics Announces Second Quarter 2017 Financial Results and Recent Highlights
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for patients with cancer and multiple sclerosis (MS), today reported financial results for the second quarter
View HTML
Toggle Summary Atara Biotherapeutics to Present at the Canaccord Genuity 37th Annual Growth Conference
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading "off-the-shelf" T-cell immunotherapy company developing novel treatments for patients with cancer and multiple sclerosis (MS), today announced that Isaac Ciechanover, M.D., the
View HTML